Health.md is a markdown-based format for structuring healthcare data that optimizes for:
patient-id.health.md
anonymous-001.health.md
john-doe-2024.health.md
---
health_md_version: "1.0"
record_id: "anonymous-001"
generated: "2024-02-17T10:00:00Z"
privacy_level: "anonymous" # anonymous, pseudonymized, identified
last_updated: "2024-02-17T10:00:00Z"
data_sources: ["epic", "manual_entry"]
---
Basic patient information required for clinical context.
## Demographics
- **Age:** 34 (or Age Range: 30-39 for privacy)
- **Sex:** Female
- **Gender Identity:** Female (optional, if different from sex)
- **Occupation:** Software Engineer (or Category: Technology)
- **Location:** Stockholm, Sweden (or Region: Northern Europe)
Privacy Levels:
anonymous: Age ranges, occupation categories, broad regionspseudonymized: Exact age, specific occupation, city-level locationidentified: Full demographics with real identifiersActive medications with clinical context.
## Current Medications
### Metformin 500mg
- **Generic Name:** Metformin Hydrochloride
- **Brand Names:** Glucophage, Fortamet
- **Indication:** Type 2 Diabetes Mellitus (ICD-10: E11)
- **Dosage:** 500mg twice daily with meals
- **Route:** Oral
- **Started:** 2024-01-15
- **Prescriber:** Dr. Smith, Endocrinology
- **Pharmacy:** Apoteket (Stockholm)
- **Insurance Coverage:** 85% covered
- **Side Effects:** None reported
- **Adherence:** Good (90%+ compliance)
- **Clinical Notes:** Well tolerated, no GI issues
### Lisinopril 10mg
- **Generic Name:** Lisinopril
- **Indication:** Hypertension (ICD-10: I10)
- **Dosage:** 10mg once daily
- **Started:** 2023-08-10
- **Clinical Notes:** Good BP control, monitoring K+ levels
Chronological record of significant medical events.
## Medical History
### Type 2 Diabetes Mellitus (2024-01-15)
- **ICD-10:** E11.9
- **Onset:** January 2024
- **Presentation:** Polyuria, polydipsia, fatigue
- **Diagnostic Criteria:** HbA1c 8.2%, Fasting glucose 180 mg/dL
- **Risk Factors:** Family history, obesity (BMI 32)
- **Treatment Response:** Good, HbA1c improved to 6.8%
### Hypertension (2023-08-10)
- **ICD-10:** I10
- **Onset:** August 2023
- **Presentation:** Elevated BP on routine screening
- **Highest Reading:** 158/96 mmHg
- **Current Status:** Well controlled (average 128/78)
Laboratory data with temporal context and clinical significance.
## Lab Results
### Hemoglobin A1C
- **2024-02-10:** 6.8% (↓ from 8.2%)
- **Reference Range:** <7.0% (ADA target for diabetes)
- **Clinical Significance:** Excellent improvement in glycemic control
- **Trend:** Decreasing (8.2% → 7.4% → 6.8%)
- **Next Due:** 2024-05-10
### Basic Metabolic Panel (2024-02-10)
- **Glucose:** 125 mg/dL (Ref: 70-100, ↓ from 180)
- **Creatinine:** 0.9 mg/dL (Ref: 0.6-1.2, stable)
- **eGFR:** >60 mL/min/1.73m² (Normal)
- **Potassium:** 4.2 mEq/L (Ref: 3.5-5.0)
- **Clinical Notes:** Monitoring for metformin/ACE inhibitor effects
### Lipid Panel (2024-01-15)
- **Total Cholesterol:** 198 mg/dL (Ref: <200)
- **LDL:** 128 mg/dL (Ref: <100, elevated)
- **HDL:** 45 mg/dL (Ref: >40 male, >50 female)
- **Triglycerides:** 156 mg/dL (Ref: <150)
- **Clinical Plan:** Recheck in 3 months, consider statin if LDL remains >100
## Allergies & Intolerances
### Drug Allergies
- **Penicillin:** Severe (anaphylaxis) - documented 2010
- **Codeine:** Moderate (nausea, vomiting)
### Environmental Allergies
- **Pollen:** Seasonal rhinitis (Spring/Summer)
- **Shellfish:** Mild (oral itching)
### Food Intolerances
- **Lactose:** Moderate (bloating, diarrhea)
## Vital Signs
### Blood Pressure (2024-02-10)
- **Reading:** 128/78 mmHg
- **Position:** Seated
- **Arm:** Left
- **Cuff Size:** Standard adult
- **Trend:** Improved from 158/96 (2023-08-10)
### Anthropometrics (2024-02-10)
- **Weight:** 78 kg (↓ from 85 kg)
- **Height:** 165 cm
- **BMI:** 28.7 (↓ from 31.2, target <25)
- **Waist Circumference:** 92 cm (↓ from 98 cm)
## Clinical Timeline
### 2024-02-10: Diabetes Follow-up
- **Provider:** Dr. Smith (Endocrinology)
- **Chief Complaint:** Routine diabetes management
- **Assessment:** Excellent glycemic control, continue current therapy
- **Plan:**
- Continue Metformin 500mg BID
- Recheck HbA1c in 3 months
- Nutrition counseling referral
- **Next Appointment:** 2024-05-10
### 2024-01-15: Initial Diabetes Diagnosis
- **Provider:** Dr. Johnson (Family Medicine)
- **Chief Complaint:** Increased thirst, frequent urination
- **Labs:** HbA1c 8.2%, Fasting glucose 180 mg/dL
- **Assessment:** Type 2 Diabetes Mellitus, newly diagnosed
- **Plan:**
- Start Metformin 500mg BID
- Diabetes education class
- Endocrinology referral
- Lifestyle modifications (diet, exercise)
## Care Team
### Primary Care
- **Dr. Sarah Johnson, MD** - Family Medicine
- **Practice:** Stockholm Family Health Center
- **Contact:** +46-8-123-4567
- **Relationship:** Primary Care Provider (2020-present)
### Specialists
- **Dr. Michael Smith, MD** - Endocrinology
- **Practice:** Karolinska Diabetes Center
- **Contact:** +46-8-987-6543
- **Relationship:** Diabetes management (2024-present)
### Pharmacy
- **Apoteket Centralstation**
- **Pharmacist:** Anna Lindberg, PharmD
- **Contact:** +46-8-555-0123
2024-02-17 or 2024-02-17T10:00:00Z2024-02 (month precision), 2024 (year precision)500mg, 10 mL/min, 78 kg(Ref: 70-100) or (Normal: <7.0%)↑, ↓, →, stable, improving, worseningE11.9 (Type 2 diabetes)44054006 (Type 2 diabetes)4548-4 (Hemoglobin A1c)6809 (Metformin)privacy_level: anonymous)privacy_level: pseudonymized)privacy_level: identified)## Mental Health History
<!-- SENSITIVE: Mental health information -->
### Major Depressive Disorder (2022-03-15)
<!-- END SENSITIVE -->
## Substance Use History
<!-- SENSITIVE: Substance use -->
- **Alcohol:** Social use, 2-3 drinks/week
- **Tobacco:** Former smoker, quit 2020
- **Illicit Drugs:** None reported
<!-- END SENSITIVE -->
<!-- EXTENSION: cardiology-v1.0 -->
## Cardiac Function
### Echocardiogram (2024-02-15)
- **EF:** 65% (Normal: >55%)
- **Wall Motion:** Normal
- **Valve Function:** Mild mitral regurgitation
<!-- END EXTENSION -->
## Device Data
### Continuous Glucose Monitor
- **Device:** Freestyle Libre 2
- **Period:** 2024-02-01 to 2024-02-14
- **Average Glucose:** 135 mg/dL
- **Time in Range:** 78% (70-180 mg/dL)
- **Time Below Range:** 2% (<70 mg/dL)
## Genomic Information
<!-- SENSITIVE: Genetic data -->
### Pharmacogenomics
- **CYP2D6:** *1/*4 (Intermediate Metabolizer)
- **Clinical Relevance:** May need adjusted dosing for codeine, metoprolol
- **Testing Date:** 2024-01-20
- **Laboratory:** GeneDx
<!-- END SENSITIVE -->
Specification Maintained By: Birger Moëll, Uppsala University
Last Updated: 2024-02-17
License: MIT